Senores Pharmaceuticals L

Senores Pharmaceuticals L (SENORES) is a small-cap Healthcare company valued at ₹6,072 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Senores Pharmaceuticals L last traded at ₹1,291.4, up 2.59% on the day.

Recent developments

On 2026-07-27, Senores Pharma reported Q1 results showing net profit rose 56% YoY to ₹31 crore, with revenue up 36%. This reflects strong performance in the quarter, contributing to the year-to-date growth in revenue and profit.

Financial performance

The company's business is improving, with annual revenue rising 59.0% and net profit surging 109.5%. The latest quarter saw revenue increase 30.6% and net profit jump 45.0% compared to the same quarter a year earlier. The net profit margin expanded 4.6 percentage points to 19.2%, while return on capital employed remained at 14.4%.

Valuation multiples

The stock trades at 51.5 times earnings, a premium to the Healthcare median of 32.0, 7.21 times book value.

Things to watch

The company has not paid any dividends despite reporting repeated profits, which may raise concerns about capital allocation. The stock is 15.6% below its 52-week high, indicating a potential pullback from recent levels. The return on equity is 0.0%, suggesting limited profitability relative to equity invested.

Where it stands

Senores Pharmaceuticals Ltd has delivered strong growth in both revenue and net profit over the past year and quarter, with margins improving significantly. The stock remains 15.6% below its 52-week high, and the company has not distributed any dividends despite consistent profitability. The most recent figure is the latest quarter net profit of ₹30 crore.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.